State Street SPDR S&P Biotech ETF
625 hedge funds and large institutions have $9.73B invested in State Street SPDR S&P Biotech ETF in 2025 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 162 increasing their positions, 276 reducing their positions, and 104 closing their positions.
22.69% more ownership
Funds ownership: 175.8% → 198.49% (+23%)
6% more capital invested
Capital invested by funds: $9.2B → $9.73B (+$531M)
0% more funds holding in top 10
Funds holding in top 10: 15 → 15 (0)
9% less funds holding
Funds holding: 685 → 625 (-60)
35% less call options, than puts
Call options by funds: $1.47B | Put options by funds: $2.24B
41% less repeat investments, than reductions
Existing positions increased: 162 | Existing positions reduced: 276
50% less first-time investments, than exits
New positions opened: 52 | Existing positions closed: 104
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$399M |
| 2 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$291M |
| 3 |
Citigroup
New York
|
+$182M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$59.4M |
| 5 |
JFG
Jefferies Financial Group
New York
|
+$50.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$246M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$199M |
| 3 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
-$48.7M |
| 4 |
Squarepoint
New York
|
-$38.6M |
| 5 |
JSAM
J. Safra Asset Management
New York
|
-$25.2M |
XBI Hedge Fund Activity: Q2 2025 in Review
625 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q2 2025, worth a combined $9.73B — up 5.8% from $9.2B a quarter earlier.
Sellers outnumbered buyers: 104 funds closed out of XBI and 52 opened new positions — a net loss of 52 holders — while 276 trimmed existing stakes and 162 added.
The largest buyer was Goldman Sachs, adding an estimated $399M. The largest seller was UBS Group, cutting an estimated $246M.
- 625 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q2 2025, down from 685 in Q1 2025.
- Funds reported $9.73B of State Street SPDR S&P Biotech ETF stock for Q2 2025, up 5.8% quarter-over-quarter.
- 52 funds opened new State Street SPDR S&P Biotech ETF positions in Q2 2025 and 104 closed out, a net change of -52 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q2 2025 was Goldman Sachs, an estimated $399M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q2 2025 was UBS Group, an estimated $246M sold.
Based on aggregated 13F filings for Q2 2025.